Product Update

tiotropium 2.5 microgram inhalation solution (Spiriva Respimat®)  
Boehringer Ingelheim Ltd

10 November 2017

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated resubmission

**tiotropium (Spiriva Respimat®)** is accepted for use within NHS Scotland.

**Indication under review:** as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).

Tiotropium (Spiriva Respimat®) was previously accepted for restricted use in patients who have poor manual dexterity and therefore have difficulty using the HandiHaler device. Since tiotropium (Spiriva) Respimat is now available at no additional cost compared with tiotropium (Spiriva) HandiHaler the restriction has been removed.

**Advice context:**

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 11 September 2017.

**Chairman,**  
Scottish Medicines Consortium

Published 11 December 2017